Physician profile
Christopher Cirulli
NPI 1821039538
$6,925.02
in general payments reported to CMS, 2019-2025
42 companies · $243 in 2025
The $243 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,487 · 2020: $1,295 · 2021: $1,521 · 2022: $1,810 · 2023: $207 · 2024: $363 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $813.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $813.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,138.37 | 2019-2023 | Xtandi |
| Abbvie INC. | $621.93 | 2019-2025 | Botox |
| Bayer Healthcare Pharmaceuticals INC. | $506.67 | 2019-2022 | |
| Antares Pharma, INC. | $467.41 | 2019-2022 | |
| Blue Earth Diagnostics | $327.72 | 2019-2022 | |
| Coloplast Corp | $317.97 | 2019-2024 | Speedicath |
| 180 Medical, INC. | $308.36 | 2019-2022 | |
| Janssen Biotech, INC. | $286.90 | 2019-2022 | |
| Tolmar Pharmaceuticals, INC. | $275.69 | 2019-2022 | |
| Myovant Sciences INC. | $274.13 | 2021-2022 | |
| Dendreon Pharmaceuticals LLC | $257.72 | 2019-2021 | |
| Urogen Pharma, INC. | $229.68 | 2020-2023 | Jelmyto |
| Ferring Pharmaceuticals INC. | $210.34 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $193.49 | 2020-2022 | |
| Calyxo, INC. | $158.49 | 2025 | Cvac Aspiration System |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Cirulli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.